Mirat Shah

14PUBLICATIONS
73CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Food properties (incl. characteristics and health benefits)Predictive and prognostic markersEnvironmental epidemiology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (14)

|Aug 27, 2025
FDA Approval Summary: Datopotamab Deruxtecan-dlnk for Treatment of Patients with Unresectable or Metastatic, HR-Positive, HER2-Negative Breast Cancer.

Melanie Royce, Mirat Shah, Lijun Zhang

|Aug 11, 2025
US Food and Drug Administration Approval Summary: Ribociclib With an Aromatase Inhibitor in the Adjuvant Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Stage II and III High-Risk Early Breast Cancer Treatment Setting.

Jennifer J Gao, Tatiana M Prowell, Haley Gittleman

|Aug 05, 2025
US Food and Drug Administration Approval Summary: Trastuzumab Deruxtecan for the Treatment of Adult Patients With Hormone Receptor-Positive, Unresectable or Metastatic Human Epidermal Growth Factor Receptor 2-Low or Human Epidermal Growth Factor Receptor 2-Ultralow Breast Cancer.

Asma Dilawari, Hui Zhang, Mirat Shah

|May 19, 2025
Overall Survival and the Evolving Benefit-Risk Assessment for Poly (ADP-ribose) Polymerase Inhibitors in Advanced Ovarian Cancer.

Mirat Shah, Ting-Yu Chen, Gwynn Ison

|May 06, 2025
Dosage Optimization of Pediatric Oncology Products: Our Patients Deserve Better.

Kristin M Wessel, Nicole Drezner, Stacy S Shord

|Jul 29, 2024
Dosage Optimization: A Regulatory Perspective for Developing Oncology Drugs.

Atiqur Rahman, Mirat Shah, Stacy S Shord

Pageof 3

Frequent Collaborators

10 joint publications

Laleh Amiri-Kordestani

9 joint publications

Richard Pazdur

7 joint publications

William Pierce

7 joint publications

Shenghui Tang